Braveheart Bio, Inc. (BRVE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Braveheart Bio, Inc. (BRVE) closed at USD 19.21 on 2026-10-19, a change of -35.5 % over the past year, with a market capitalization of USD 1.83B.

Braveheart Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Braveheart Bio, Inc. key figures

Previous close

USD 19.21 (2026-10-19)

1-year change

-35.5 %

Market cap

USD 1.83B

Enterprise value

USD 1.75B

P/E ratio (trailing)

-3.33

P/E ratio (forward)

-10.19

EPS (trailing)

-6.08

EPS (forward)

-1.99

PEG ratio

n/a

Price to book

-1.59

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.92

Employees

49

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Braveheart Bio, Inc.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Braveheart Bio, Inc. and compare it with other stocks.